TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28440034

Group type: EXPERIMENTAL
Intervention: Real tDCS (2 mA, 20 min, anodal stimulation over M1 for 4 consecutive days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 50
Study: 25716971

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day for 12 weeks
Number of subjects: 18
Study: 22700526

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) received a month of weekly 4-hour training for nursing home staff.
Number of subjects: 230

Group type: COMPARATOR
Intervention: Reference Group (RG) did not receive the training.
Number of subjects: 230
Study: 21381995

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Team Care Arrangements (TCAs)
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Patient Assessment of Chronic Illness Care (PACIC) scores for patients with TCAs
Number of subjects: 1752

Group type: COMPARATOR
Intervention: Control group (no TCA)
Number of subjects: 1752
Study: 19919298

Group type: EXPERIMENTAL
Intervention: Text presentation format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graphic presentation format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of text and graphics presentation format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall comprehension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calculation and operations numeracy skill
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health literacy skill and income
Number of subjects: 0
Study: 16500498

Group type: EXPERIMENTAL
Intervention: Coronary flow velocity pattern assessed by transthoracic color Doppler echocardiography (TTCDE)
Number of subjects: 64
Study: 10989321

Group type: EXPERIMENTAL
Intervention: Doxazosin (1-4 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (without doxazosin)
Number of subjects: 19
Study: 9194510

Group type: EXPERIMENTAL
Intervention: alpha-methyldopa
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: combination of hydrochlorothiazide and amiloride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: amlodipine and combined diuretics
Number of subjects: 24

Group type: COMPARATOR
Intervention: alpha-methyldopa and combination of hydrochlorothiazide and amiloride
Number of subjects: 24
Study: 8363072

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1 mg morphine in saline
Number of subjects: 120

Group type: COMPARATOR
Intervention: 2 mg morphine in saline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1 mg morphine in 0.25% bupivacaine
Number of subjects: 120
Study: 3929694

Group type: EXPERIMENTAL
Intervention: FT + PSK
Number of subjects: 3630

Group type: EXPERIMENTAL
Intervention: PSK, MMC and FT combination
Number of subjects: 3630

Group type: EXPERIMENTAL
Intervention: PSK, OK, MMC and FT
Number of subjects: 3630

Group type: EXPERIMENTAL
Intervention: PSK administration
Number of subjects: 3630

Group type: EXPERIMENTAL
Intervention: PSK and/or OK with MMC and FT
Number of subjects: 3630
Study: 29650130

Group type: EXPERIMENTAL
Intervention: Single-session group mantra-meditation for 20 minutes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Single-session group mantra-meditation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no meditation)
Number of subjects: 30
Study: 25582434

Group type: EXPERIMENTAL
Intervention: Compression socks (COMP) worn during exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON) with no compression socks worn
Number of subjects: 10
Study: 23914814

Group type: EXPERIMENTAL
Intervention: Death prime
Number of subjects: 377

Group type: COMPARATOR
Intervention: Pain prime (control)
Number of subjects: 377
Study: 22823253

Group type: EXPERIMENTAL
Intervention: Fresh breastmilk
Number of subjects: 18

Group type: COMPARATOR
Intervention: Thawed breastmilk
Number of subjects: 18
Study: 21401248

Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 355

Group type: COMPARATOR
Intervention: Gain-framed message
Number of subjects: 355
Study: 18182964

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Clonidine and Methylphenidate
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 16645424

Group type: EXPERIMENTAL
Intervention: K-Mg-citrate (42 mEq K/d and 21 mEq Mg/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: KCl (42 mEq/d)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: K-Mg-citrate
Number of subjects: 22

Group type: COMPARATOR
Intervention: KCl
Number of subjects: 22
Study: 12870137

Group type: EXPERIMENTAL
Intervention: Yearly chest radiographs to detect second primaries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine use of computed axial tomography (CAT) scans, bone scans, brain imaging, and serum tumor markers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adherence to breast cancer follow-up clinical practice guidelines
Number of subjects: 0
Study: 10816061

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 19
Study: 8727400

Group type: EXPERIMENTAL
Intervention: Stepping forward in response to backward surface translation with predictable perturbation velocities (blocked order)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Stepping forward in response to backward surface translation with unpredictable perturbation velocities (random order)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Maintaining stance during backward surface translation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Stepping forward in response to surface perturbation regardless of velocity presentation order
Number of subjects: 11
Study: 1840065

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional antidepressants
Number of subjects: 24
Study: 6974303

Group type: EXPERIMENTAL
Intervention: Enpryn, capsules containing enteric‐coated pellets
Number of subjects: 11

Group type: COMPARATOR
Intervention: Rhusal, an enteric‐coated tablet
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Enteric‐coated pellet capsules
Number of subjects: 11
Study: 31693540

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (standard condition)
Number of subjects: 117
Study: 30692123

Group type: EXPERIMENTAL
Intervention: MAA868, single subcutaneous doses
Number of subjects: 0
Study: 28883521

Group type: EXPERIMENTAL
Intervention: Maternal obesity
Number of subjects: 48919
Study: 25880636

Group type: EXPERIMENTAL
Intervention: Intermittent CVR use (to allow menstruation)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Continuous CVR use
Number of subjects: 120
Study: 23929148

Group type: EXPERIMENTAL
Intervention: Anterior nasal packing
Number of subjects: 73

Group type: COMPARATOR
Intervention: No anterior nasal packing
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both groups (packed and not packed)
Number of subjects: 73
Study: 21545397

Group type: EXPERIMENTAL
Intervention: Low-dose valsartan (10/20 mg)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Medium-dose valsartan (40/80 mg)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: High-dose valsartan (80/160 mg)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Pooled valsartan group
Number of subjects: 261

Group type: COMPARATOR
Intervention: Pooled placebo group
Number of subjects: 261
Study: 17886168

Group type: EXPERIMENTAL
Intervention: HF-rTMS on left DLPFC
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HF-rTMS on right DLPFC
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham HF-rTMS
Number of subjects: 54
Study: 16871272

Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15104857

Group type: EXPERIMENTAL
Intervention: No noise and no interruption
Number of subjects: 48

Group type: COMPARATOR
Intervention: Noise and interruption
Number of subjects: 48
Study: 11353877

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (lisinopril, 20 mg od)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (lisinopril)
Number of subjects: 58
Study: 9398953

Group type: EXPERIMENTAL
Intervention: Intravenous regional anaesthesia (IVRA)
Number of subjects: 121

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 121
Study: 8184233

Group type: EXPERIMENTAL
Intervention: Air-filled balls (Pezziballs)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional seating
Number of subjects: 46
Study: 3310158

Group type: EXPERIMENTAL
Intervention: Diltiazem 10 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Diltiazem 5 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 7
Study: 29283679

Group type: EXPERIMENTAL
Intervention: Orthokeratology lens (treatment)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional rigid gas permeable lens (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both eyes (treatment and control)
Number of subjects: 16
Study: 27253993

Group type: EXPERIMENTAL
Intervention: Family presence during CPR
Number of subjects: 75
Study: 25709399

Group type: EXPERIMENTAL
Intervention: AZD3199 via a Spira nebulizer (Turbuhaler; equivalent delivered doses 5‐3200 μg) or Turbuhaler (single delivered doses of 120‐1920 μg or repeated delivered once‐daily doses 240‐1,680 μg)
Number of subjects: 0
Study: 23926651

Group type: EXPERIMENTAL
Intervention: Acute hypobaric hypoxia (10,000 m altitude)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (sea level)
Number of subjects: 28
Study: 20876601

Group type: EXPERIMENTAL
Intervention: Gold-tip catheter
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control catheter
Number of subjects: 463
Study: 18676275

Group type: EXPERIMENTAL
Intervention: Preoperative regional intra-arterial chemotherapy (PRAC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Surgical resection only
Number of subjects: 45
Study: 16169761

Group type: EXPERIMENTAL
Intervention: Inhaled Formoterol 9 microg bid
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 12648711

Group type: COMPARATOR
Intervention: Fotemustine alone (arm A)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Fotemustine plus whole brain irradiation (arm B)
Number of subjects: 76
Study: 10714479

Group type: EXPERIMENTAL
Intervention: High respirable dose formulation at 30 l min(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High respirable dose formulation at 60 l min(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low respirable dose formulation at 30 l min(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low respirable dose formulation at 60 l min(‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of urinary excretion between formulations
Number of subjects: 24
Study: 8774398

Group type: EXPERIMENTAL
Intervention: Medium dose subcutaneous heparin (12,500 units twice per day)
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Low dose subcutaneous heparin (5000 units twice per day)
Number of subjects: 984

Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily)
Number of subjects: 984

Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 984
Study: 1282178

Group type: EXPERIMENTAL
Intervention: Nicorandil (10 or 20 mg b.i.d.)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Propranolol (40 or 80 mg t.i.d.)
Number of subjects: 77
Study: 6380286

Group type: EXPERIMENTAL
Intervention: Staging by laparotomy (Group I)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Staging by closed techniques (Group II)
Number of subjects: 104
Study: 31004969

Group type: EXPERIMENTAL
Intervention: Free from Falls Online (FFFO) - eight weekly sessions with instructional and exercise components
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group - received a brochure on minimizing fall risk and a letter to their treating physician
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Free from Falls Online (FFFO)
Number of subjects: 30
Study: 28662279

Group type: EXPERIMENTAL
Intervention: E‐MPA
Number of subjects: 24

Group type: COMPARATOR
Intervention: CsA‐MPA
Number of subjects: 24
Study: 26031820

Group type: EXPERIMENTAL
Intervention: Operative intervention for acute cholecystitis
Number of subjects: 1399

Group type: EXPERIMENTAL
Intervention: Postoperative treatment for acute cholecystitis
Number of subjects: 1399
Study: 24164228

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (InGaAlP laser)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham laser (control)
Number of subjects: 60
Study: 20390249

Group type: EXPERIMENTAL
Intervention: Mini-midvastus (MMV) approach
Number of subjects: 30

Group type: COMPARATOR
Intervention: Limited medial parapatellar (LMPP) approach
Number of subjects: 30
Study: 19567213

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study: 17024797

Group type: EXPERIMENTAL
Intervention: Kanamycin (100 mg vaginal ovules for 6 days)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Meclocycline (35 mg vaginal ovules for 6 days)
Number of subjects: 81
Study: 12835609

Group type: EXPERIMENTAL
Intervention: Audio Computer-assisted Self-interviewing
Number of subjects: 69
Study: 10685667

Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 281

Group type: COMPARATOR
Intervention: IL-2 and IFN-alpha combination
Number of subjects: 281

Group type: COMPARATOR
Intervention: IFN-alpha alone
Number of subjects: 281

Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 281
Study: 8775698

Group type: EXPERIMENTAL
Intervention: Postoperative physical therapy plus continuous passive motion (CPM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Postoperative physical therapy (Control)
Number of subjects: 26
Study: 1289413

Group type: EXPERIMENTAL
Intervention: IFN-alpha 2b, 20 million units/m2 i.v. 5 days/week x 4, then 10 million units s.c.t.i.w.
Number of subjects: 87

Group type: COMPARATOR
Intervention: IFN-beta ser, 180 million units t.i.w.
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: IFN-alpha 2b
Number of subjects: 87

Group type: COMPARATOR
Intervention: IFN-beta ser
Number of subjects: 87
Study: 6150000

Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Guanfacine (2 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alpha-methyldopa
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: RX 781094 (0.3 mg/kg)
Number of subjects: 12
Study: 30230920

Group type: EXPERIMENTAL
Intervention: HIIERPE (high-intensity interval exercise prescribed and self-regulated by RPE, 25 min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: HIIEHR (high-intensity interval exercise prescribed and regulated by HR response to CPX, 25 min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MICE (continuous moderate-intensity exercise, 30 min)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (30 min of seated resting)
Number of subjects: 11
Study: 30394151

Group type: EXPERIMENTAL
Intervention: Training (5-hour training for GPs)
Number of subjects: 640
Study: 26851191

Group type: EXPERIMENTAL
Intervention: Personalized intervention group (disclosure of FTO risk)
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: Personalized intervention group (encouraged to increase PA)
Number of subjects: 1279

Group type: COMPARATOR
Intervention: Nonrisk participants (disclosure of genotype)
Number of subjects: 1279

Group type: COMPARATOR
Intervention: Baseline PA measurement
Number of subjects: 1279
Study: 24532078

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg/die for 2 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 11
Study: 21075465

Group type: EXPERIMENTAL
Intervention: Pitavastatin (2mg/day)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Conventional therapy for heart failure
Number of subjects: 577
Study: 20397457

Group type: EXPERIMENTAL
Intervention: Body acupuncture plus auricular‐plaster therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (Baihui (GV 20)‐through‐Sishencong (EX‐HN1) puncture, auricular‐plaster therapy and moxibustion on the back‐shu points not used)
Number of subjects: 90
Study: 17666604

Group type: EXPERIMENTAL
Intervention: Tinidazole 1 g once daily for 5 days
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g once daily for 2 days
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 15644654

Group type: EXPERIMENTAL
Intervention: Airway pressure signal (Paw) added to pressure tracings
Number of subjects: 121

Group type: COMPARATOR
Intervention: No airway pressure signal (Paw)
Number of subjects: 121
Study: 12244386

Group type: EXPERIMENTAL
Intervention: 0.1 mg/Kg chlorpromazine intravenously
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (10 ml of saline intravenous injections)
Number of subjects: 30
Study: 9988395

Group type: EXPERIMENTAL
Intervention: Oral estrogen (E2 valerate, 2 mg/d) plus medroxyprogesterone acetate (5 mg/d) administered during weeks 3, 4, 7, and 8 for 8 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (50‐microg or 100‐microg E2 patch)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (Seventeen premenopausal women)
Number of subjects: 36
Study: 7564363

Group type: EXPERIMENTAL
Intervention: Remikiren (single oral administration)
Number of subjects: 16
Study: 2197005

Group type: COMPARATOR
Intervention: 5% lidocaine 0.5 mg.kg‐1 in 7.5% glucose (n = 20)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 5% meperidine 0.5 mg.kg‐1 (n = 22)
Number of subjects: 42
Study: 6448650

Group type: EXPERIMENTAL
Intervention: zimelidine
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 30991945

Group type: EXPERIMENTAL
Intervention: Confusion Assessment Method (CAM) assessment training
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CAM assessments conducted by trained research assistants
Number of subjects: 37
Study: 28821260

Group type: EXPERIMENTAL
Intervention: GFF MDI (glycopyrrolate/formoterol fumarate 18/9.6 μg) administered twice daily
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: GFF MDI
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 110
Study: 26122460

Group type: EXPERIMENTAL
Intervention: PACES intervention (8-week group sessions co-led by a psychologist and trained peer with epilepsy)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: PACES intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 83
Study: 24499425

Group type: EXPERIMENTAL
Intervention: Self-care acupressure
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 220
Study: 20922438

Group type: EXPERIMENTAL
Intervention: zoledronic acid
Number of subjects: 323

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 323
Study: 19074663

Group type: EXPERIMENTAL
Intervention: Continuous highly active antiretroviral therapy (HAART) for 24 months (arm A)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Intermittent highly active antiretroviral therapy (HAART) for 24 months (arm B)
Number of subjects: 58
Study: 16705107

Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/d
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Policosanol 20 mg/d
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Policosanol 40 mg/d
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Policosanol 80 mg/d
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 12125326

Group type: EXPERIMENTAL
Intervention: Evidence-based practice in dentistry
Number of subjects: 0
Study: 10071280

Group type: EXPERIMENTAL
Intervention: Consolidation radiotherapy (RT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No consolidation radiotherapy (RT)
Number of subjects: 100
Study: 7545448

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (5 g total)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) kallikrein inhibitory units total)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (neither drug nor placebo)
Number of subjects: 75
Study: 2341581

Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Ketorolac 90 mg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Pethidine 100 mg
Number of subjects: 121
Study: 7000136

Group type: EXPERIMENTAL
Intervention: Oral psoralen and long-wave ultraviolet light (treated side)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Topical psoralen and long-wave ultraviolet light (previously control side)
Number of subjects: 22
Study: 31783132

Group type: EXPERIMENTAL
Intervention: Spicy stimulation
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Spicy food consumption ≥3 days/week
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sweet stimulation
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Long-term spicy diet
Number of subjects: 160
Study: 29361199

Group type: EXPERIMENTAL
Intervention: Mavrilimumab 100 mg every other week plus methotrexate
Number of subjects: 442

Group type: COMPARATOR
Intervention: Mavrilimumab (30, 100, or 150 mg) or placebo every other week plus methotrexate
Number of subjects: 442
Study: 28456025

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 75
Study: 26297124

Group type: EXPERIMENTAL
Intervention: Di-Huang-Yi-Zhi (DHYZ) with donepezil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Donepezil (5 mg for 1 month, then 10 mg for the rest of the months, once daily)
Number of subjects: 60